harp biotech bite amgn/regn
highlight buy goonewerden t-cell engag platform play read-across
strh biotech analyst goonewarden launch coverag
buy platform compani develop t-cell engag tritac read-across two compani
coverag univers robust bite/bispecf platform valid
approv blincyto r/r b-cell see initi bispecif platform use
velocibi platform start yield fruit clinic encourag human data initi
shown earli encourag data earli assign valu view
sever bispecif alreadi clinic shown encourag initi in-
human data accept safety/toler profil continu await addit data conduct
due dilig assign credit platform candid howev expect see read-through
platform next month data emerg player field
harp tritac platform similar amgn bite clinic data need realist
comparison notabl see read-through bite platform micromet acquisit
given co-found cso micromet oversaw devleop bite
highlight tritac differ approach bite await see clinic data
see modal compar
highlight sever tidbit bite bispecif candid
relat
believ multipl myeloma
prostat cancer commerci viabl note report due continu
iv administr short half-lif bite provid proof-of-concept data behind next-gen
hle-bit develop hle bite addit hle domain prolong
vivo half-lif allow weekli infus develop hle-bit
bite show car-t-lik efficaci read-through hle-bit
fih dose escal data expect continu iv short half-lif bite show clinic
activ heavili pre-treat r/r mm patient base data present
show orr respond achiev mrd- cr respons start
first cycl respons last median month rang see robust
efficaci profil note observ tox observ
use fc domain longer serum half-lif potenti weekli infus circumv continu infus issu
await phase data preclin data shown enhanc prolifer cell effector t-cell function induc t-cell mediat
lysi vitro await clinic data get comfort around safeti efficaci fc region play role mediat effector function involv
immune-meid cell-kil mechan cdc adcc howev could modifi glycoengin chang amino acid sequenc
fc region enhance/diminish immune-medi cell kill via antibodi
continu iv prostat cancer shown accept safeti dose-depend clinic activ mcrpc patient
await hle-bit data current dose escal see safety/efficaci shake data look encourag
formal respond reduct durabl last year durat
page
valuat risk
target price deriv dcf assum legaci sale declin non-legaci peak sale
adjust pipelin sale use discount rate appropri lower risk biotech use higher
termin valu vs model beyond patent cliff believ use capit product
risk rate price target includ on-going generic/biosimilar competit part price pressur poorer expect sale
valuat risk
pt deriv probabl adjust dcf use discount rate line larg cap biotech compani
assign termin growth rate account pipelin assign valu pipelin upsid risk includ dupix beat
expect compani provid greater clariti oncolog strategi downsid risk includ eylea biosimilar enter market
earlier expect dupix uptak poorer anticip better data competit versu dupix clariti implement
price
compani mention note
robyn karnauska herebi certifi view express research report accur reflect person view subject
compani secur also certifi receiv direct indirect compens
exchang express specif recommend report
suntrust robinson humphrey inc make market follow compani amgn-u regn-u harp-u
analyst compens base upon stock price perform qualiti analysi commun skill overal revenu profit
firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif research rate specif target price
consider induc receipt busi compens addit associ person prepar research report prohibit
own secur subject compani
page
rate price target histori amgen inc amgn-u
rate price target histori inc regn-u
creat bluematrix
rate price target histori inc harp-u
creat bluematrix
strh rate system equiti secur
dissemin research
creat bluematrix
page
suntrust robinson humphrey strh seek make reason effort provid research report simultan elig client
report avail publish restrict access area websit elig client request password institut
investor corpor member press may also receiv research via third parti vendor includ thomson reuter bloomberg
factset capit iq addit distribut may done sale personnel via email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/librari jsp
pleas email research depart contact strh sale repres
strh rate equiti secur
suntrust robinson humphrey strh rate individu equiti use three-tier system stock rate rel broader market
gener next month unless otherwis indic
buy stock total return expect outperform relev benchmark next month unless otherwis
hold stock total return expect perform line relev benchmark next month unless
sell stock total return expect under-perform relev benchmark next month unless otherwis
rate nr strh invest rate opinion stock
coverag suspend cs indic strh rate and/or target price temporarili suspend due applic regul
and/or strh manag discret previous publish rate target price reli upon
strh analyst price target stock cover unless otherwis indic price target repres analyst expect
stock trade next month unless otherwis indic analyst believ insuffici valuat
driver and/or invest catalyst deriv posit neg invest view may elect approv strh research
manag assign target price likewis certain stock trade may exhibit volatil wherebi assign price target would
unhelp make invest decis research manag approv analyst may refrain assign target
legend rate price target histori chart
page
suntrust robinson humphrey rate distribut
